REVB (Revelation Biosciences) Research & Development: $4.58 Mil (TTM As of Mar. 2026)


REVB Revelation Biosciences Inc REVB
28 GF Score
Price $0.98
! 1 Warning Sign
View Full Analysis

What is Revelation Biosciences Research & Development?

Revelation Biosciences REVB +3.16% 28 Research & Development is $4.58 Mil as of Mar. 2026. GuruFocus rates REVB with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Revelation Biosciences's Research & Development for the three months ended in Mar. 2026 was $1.38 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $4.58 Mil.

Revelation Biosciences  (NAS:REVB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Revelation Biosciences Research & Development Related Terms

Revelation Biosciences Research & Development Historical Data

* Premium members only.

The historical data trend for Revelation Biosciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revelation Biosciences Research & Development Chart

Revelation Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 6.92 5.38 4.15 3.55 4.06

Revelation Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 1.32 0.92 0.96 1.38
REVB
28GF Score
Revelation Biosciences Inc REVB
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Revelation Biosciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $4.58 Mil mean?
Revelation Biosciences (REVB) has a Research & Development of $4.58 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Revelation Biosciences and its competitors.
Is Revelation Biosciences' Research & Development too high?
Revelation Biosciences' current Research & Development is $4.58 Mil. Overall, Revelation Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Revelation Biosciences' Research & Development compare to ITRMF and ENSC?
Revelation Biosciences' Research & Development of $4.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Revelation Biosciences and its competitors. Revelation Biosciences's current Research & Development is $4.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revelation Biosciences stock overvalued right now?
Revelation Biosciences (REVB) has a current Research & Development of $4.58 Mil. The current Research & Development is $4.58 Mil. Revelation Biosciences' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Revelation Biosciences (REVB), the current Research & Development is $4.58 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Revelation Biosciences Business Description

Address 4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
28GF Score

Get the complete analysis for REVB

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.98
Price